Get notified when NWBO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- 9,700,000 Shares Offered By Selling Stockholders (new) — A significant portion of the offering is secondary, with proceeds going to insiders rather than the company.
- Net Tangible Book Value Per Share Is Negative At $(0.06) Before and $(0.05) After the Offering (new) — Investors are paying $0.171 per share for a company with negative tangible book value, indicating substantial dilution.
- Management Has Significant Discretion and Flexibility In Applying the Net Proceeds (new) — No specific allocations for the $4.7M net proceeds are determined, giving investors limited visibility into capital deployment.
Northwest Biotherapeutics registers 40.3M shares for $4.9M convertible note and $2M warrant financing at $0.17/share
Filed July 31, 2026 · ~1 min read
Key Changes
-
high
NWBO registers 40,325,000 shares for a $4.9M convertible note and $2M warrant financing with YA II PN, Ltd.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $4.7M (4,655,000) after OID, facility commitment fee and expenses.
The Offering verify on EDGAR → -
high
9,700,000 shares are offered by selling stockholders; proceeds from those shares go to those insiders, not the company.
The Offering verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PATH 10-Q) is open in full — no account needed.
Partner
Trade NWBO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify